No connection

Search Results

APLM vs ZYBT

APLM
Apollomics, Inc.
BEARISH
Price
$19.90
Market Cap
$42.7M
Sector
Healthcare
AI Confidence
85%
ZYBT
Zhengye Biotechnology Holding Limited
BEARISH
Price
$0.92
Market Cap
$43.6M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
APLM
--
ZYBT
--
Forward P/E
APLM
-30.62
ZYBT
--
P/B Ratio
APLM
-4.99
ZYBT
1.01
P/S Ratio
APLM
6.15
ZYBT
0.28
EV/EBITDA
APLM
-0.78
ZYBT
-66.84

Profitability

Gross Margin
APLM
100.0%
ZYBT
37.37%
Operating Margin
APLM
-124.8%
ZYBT
-46.33%
Profit Margin
APLM
0.0%
ZYBT
-12.6%
ROE
APLM
-380.13%
ZYBT
-6.38%
ROA
APLM
-72.29%
ZYBT
-3.45%

Growth

Revenue Growth
APLM
380.8%
ZYBT
-34.4%
Earnings Growth
APLM
--
ZYBT
--

Financial Health

Debt/Equity
APLM
--
ZYBT
0.23
Current Ratio
APLM
0.97
ZYBT
1.49
Quick Ratio
APLM
0.91
ZYBT
1.0

Dividends

Dividend Yield
APLM
--
ZYBT
--
Payout Ratio
APLM
0.0%
ZYBT
0.0%

AI Verdict

APLM BEARISH

APLM's Piotroski F-Score of 3/9 indicates weak financial health, with significant red flags in profitability, cash flow, and leverage. The company exhibits extreme negative profitability metrics, including a -124.8% operating margin and -380.13% ROE, despite a 380.8% YoY revenue growth. With no Altman Z-Score available and a current ratio of 0.97, liquidity concerns persist. The stock trades at a high Price/Sales of 6.15 and a negative forward P/E of -30.62, suggesting valuation is driven by speculative growth expectations rather than fundamentals. The 52-week price range of $3.66 to $42.12 reflects extreme volatility, and the 5-year return of -98.0% underscores long-term underperformance.

Strengths
380.8% YoY revenue growth indicates strong top-line expansion
100.0% gross margin suggests efficient cost structure on sales
Recent 6-month return of +191.4% shows strong short-term momentum
Risks
Piotroski F-Score of 3/9 signals severe financial distress and weak operational health
Negative ROE (-380.13%) and ROA (-72.29%) indicate deep losses relative to equity and assets
Operating margin of -124.8% reflects unsustainable cost structure or one-time expenses
ZYBT BEARISH

ZYBT presents a high-risk profile characterized by a catastrophic price collapse and severe revenue contraction. While the Piotroski F-Score of 5/9 suggests stable internal financial health and the low Debt/Equity ratio (0.23) indicates minimal leverage, these are overshadowed by a -34.40% YoY revenue decline and negative operating margins. The stock is currently trading near its 52-week low after a massive 88.2% one-year decline, signaling a complete loss of investor confidence. Despite a low Price/Sales ratio of 0.28, the lack of growth and profitability makes the current valuation a value trap.

Strengths
Stable Piotroski F-Score (5/9)
Low Debt/Equity ratio (0.23)
Healthy Current Ratio (1.49)
Risks
Severe revenue contraction (-34.40% YoY)
Deeply negative operating margins (-46.33%)
Catastrophic price performance (-88.2% 1Y)

Compare Another Pair

APLM vs ZYBT: Head-to-Head Comparison

This page compares Apollomics, Inc. (APLM) and Zhengye Biotechnology Holding Limited (ZYBT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile